Literature DB >> 27761720

Further Evaluation of Covariate Analysis using Empirical Bayes Estimates in Population Pharmacokinetics: the Perception of Shrinkage and Likelihood Ratio Test.

Xu Steven Xu1, Min Yuan2, Haitao Yang3, Yan Feng4, Jinfeng Xu5, Jose Pinheiro6.   

Abstract

Covariate analysis based on population pharmacokinetics (PPK) is used to identify clinically relevant factors. The likelihood ratio test (LRT) based on nonlinear mixed effect model fits is currently recommended for covariate identification, whereas individual empirical Bayesian estimates (EBEs) are considered unreliable due to the presence of shrinkage. The objectives of this research were to investigate the type I error for LRT and EBE approaches, to confirm the similarity of power between the LRT and EBE approaches from a previous report and to explore the influence of shrinkage on LRT and EBE inferences. Using an oral one-compartment PK model with a single covariate impacting on clearance, we conducted a wide range of simulations according to a two-way factorial design. The results revealed that the EBE-based regression not only provided almost identical power for detecting a covariate effect, but also controlled the false positive rate better than the LRT approach. Shrinkage of EBEs is likely not the root cause for decrease in power or inflated false positive rate although the size of the covariate effect tends to be underestimated at high shrinkage. In summary, contrary to the current recommendations, EBEs may be a better choice for statistical tests in PPK covariate analysis compared to LRT. We proposed a three-step covariate modeling approach for population PK analysis to utilize the advantages of EBEs while overcoming their shortcomings, which allows not only markedly reducing the run time for population PK analysis, but also providing more accurate covariate tests.

Entities:  

Keywords:  covariate; empirical bayes estimates; likelihood ratio test; population pharmacokinetics; shrinkage

Mesh:

Year:  2016        PMID: 27761720     DOI: 10.1208/s12248-016-0001-4

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  16 in total

1.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

2.  Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.

Authors:  M Davidian; A R Gallant
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

Review 3.  Covariate pharmacokinetic model building in oncology and its potential clinical relevance.

Authors:  Markus Joerger
Journal:  AAPS J       Date:  2012-01-25       Impact factor: 4.009

4.  Mixed-effects nonlinear regression for unbalanced repeated measures.

Authors:  E F Vonesh; R L Carter
Journal:  Biometrics       Date:  1992-03       Impact factor: 2.571

5.  A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.

Authors:  P O Maitre; M Bührer; D Thomson; D R Stanski
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

6.  Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Authors:  Radojka M Savic; Mats O Karlsson
Journal:  AAPS J       Date:  2009-08-01       Impact factor: 4.009

7.  Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact.

Authors:  Xu Steven Xu; Min Yuan; Mats O Karlsson; Adrian Dunne; Partha Nandy; An Vermeulen
Journal:  AAPS J       Date:  2012-09-20       Impact factor: 4.009

8.  The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model.

Authors:  Adeline Samson; Marc Lavielle; France Mentré
Journal:  Stat Med       Date:  2007-11-30       Impact factor: 2.373

9.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12

10.  Powers of the likelihood ratio test and the correlation test using empirical bayes estimates for various shrinkages in population pharmacokinetics.

Authors:  F P Combes; S Retout; N Frey; F Mentré
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-04-09
View more
  2 in total

1.  Covariates in Pharmacometric Repeated Time-to-Event Models: Old and New (Pre)Selection Tools.

Authors:  Sebastiaan C Goulooze; Elke H J Krekels; Thomas Hankemeier; Catherijne A J Knibbe
Journal:  AAPS J       Date:  2018-12-18       Impact factor: 4.009

2.  "De-Shrinking" EBEs: The Solution for Bayesian Therapeutic Drug Monitoring.

Authors:  Sarah Baklouti; Peggy Gandia; Didier Concordet
Journal:  Clin Pharmacokinet       Date:  2022-02-04       Impact factor: 5.577

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.